Sarepta to present 3-year EMBARK data for Elevidys at WMS 2026
SRPT•Sarepta said it will present three-year EMBARK study follow-up and other Duchenne muscular dystrophy data at the World Muscle Society congress, scheduled for Sept. 29-Oct. 3.
1. Planned presentations
A late-breaking poster will cover efficacy and safety outcomes for Elevidys in ambulatory patients treated at ages 8-12. Other presentations will include pooled safety data from Phase 1-3 trials and Phase 3 results for golodirsen and casimersen versus placebo.
